RHEUMATOID arthritis (RA) is associated with anaemia in up to 50% of patients [1] , with iron de®ciency and anaemia of chronic disease (ACD) being the most common causes. The pathogenesis of ACD has not been fully established and probably includes several mechanisms, including abnormalities of iron absorption [2] and release from macrophages [3] , as well as dysregulation of the cytokine network. Erythropoietin (EPO) is the major physiological growth factor for red blood cell development and studies show that although EPO levels are raised in anaemic RA patients, they are not as high as in equally anaemic iron-de®cient controls [4±6], suggesting that there is de®cient EPO production in RA. This may be related to the ®nding that altered intracellular iron balance in ACD has been shown to regulate EPO production both in vitro and in vivo, possibly via modulation of the hypoxia-sensitive haem protein which is thought to regulate EPO gene expression [7] . Reports of successful treatment of ACD with recombinant EPO therapy in RA [8±11], as well as chronic renal disease [12, 13] and in¯am-matory bowel disease [14] , support this notion. However, patients with more active rheumatoid disease show a slower improvement in haemoglobin levels in response to recombinant human (rh) EPO [15] , suggesting that other factors may also be important.
There is growing evidence to suggest that in¯am-matory cytokines, particularly tumour necrosis factor a (TNF-a), interleukin-1 (IL-1), interleukin-6 (IL-6) and interferon-g [16, 17] , contribute to ACD in RA.
TNF-a has been shown to inhibit macrophage iron release in vitro [18] , and animals treated with TNF-a develop anaemia with a low serum iron and preserved iron stores [19] . TNF-a also inhibits the formation of early red cell colonies in bone marrow cultures in vitro [20±22] and in vivo [19] . Studies using mice de®cient for either the p55 or the p75 kDa TNF receptors have indicated that this eect is mediated principally by the p55 TNF receptor, possibly through inhibition of cycling of red cell precursors from the G 0 /G 1 to the S phase [23] . The reduction in erythroid colony formation can be partly overcome in vitro by adding excess EPO to the culture system, resulting in a dose-dependent restoration of red cell colony numbers [11] . In vivo, EPO administration prevents some of the suppressive eects seen on red cell formation in TNF-a-treated mice, also in a dosedependent fashion [24] . Serum levels of TNF-a have been shown to correlate inversely with haemoglobin (Hb) as well as parameters of disease activity in RA patients with ACD [25, 26] . These ®ndings suggest that TNF-a may contribute to ACD by reducing the sensitivity of erythroblasts to EPO.
IL-6 also has diverse haematological eects and causes reversible anaemia when administered in vivo, both in animal models [27] , and following therapy for malignancies in humans [28, 29] . The underlying mechanism has not been fully established, although a haemodilutional eect has been postulated [30] . Circulating IL-6 levels have been shown to be highest amongst RA patients with ACD [31] , although this may be a re¯ection of disease activity rather than implying a direct eect of IL-6 on erythropoiesis. IL-1, like TNF-a, has a pro-in¯am-matory role in RA and has been shown to inhibit red cell colony formation both in vitro [32] and in vivo; its eects can be prevented by the simultaneous administration of EPO [33, 34] . Bone marrow macro-phages do not appear to be the major site of production of IL-1 and TNF-a in ACD, as removal of CD14-positive cells (macrophages) from the in vitro marrow culture system does not restore red cell numbers [35] .
We have previously reported [36] that RA patients treated with a chimeric antibody to TNF-a, cA2, showed signi®cant improvements relative to placebo in disease activity measures such as joint score and C-reactive protein (CRP). In addition, we saw improvements in Hb levels in cA2-treated patients, despite repeated venesection. The aim of this study was to investigate the mechanism underlying the recovery from ACD in patients treated with cA2. In particular, we focused on circulating EPO, and related changes in this growth factor to changes in Hb in RA patients with ACD.
MATERIALS AND METHODS

Study design
Details have been published previously [36] . Brie¯y, 73 patients were enrolled in a double-blind placebo-controlled trial of a chimeric monoclonal antibody to TNF-a (cA2, IgG1k isotype). All patients had active RA [de®ned as at least six swollen joints as well as 3/4 of the following: six or more tender/ painful joints, early morning stiness e45 min, erythrocyte sedimentation rate (ESR) e28 mm/h, CRP e20 mg/l]. All patients had had RA for at least 6 months (ful®lling the ACR criteria [37] ), and had failed at least one disease-modifying agent. Patients were randomly assigned to receive single infusions of either cA2 (1 or 10 mg/kg) or placebo (human albumin).
Sample collection
Peripheral blood samples from 64 of these patients were used for the purpose of this study, with venesection being performed immediately prior to infusion (week 0, mean time 08:30 a.m.), and at 2 and 4 weeks post-infusion (mean time of blood sampling 10:45 a.m.). In two patients, 2 week samples were unavailable and so week 1 samples were substituted. In two dierent patients, samples 3 weeks post-infusion were used instead of 4 weeks, for the same reason. For the preparation of serum, blood was collected into sterile tubes, allowed to clot for 30 min and spun at room temperature for 20 min at 2500 r.p.m. Serum was aliquoted into plastic tubes and stored at À708C until assayed. For the measurement of Hb, blood was collected into sterile EDTA tubes and analysed the same day. A total of H500 ml of blood were venesected from each patient during the course of the study.
Assay methods
Peripheral blood samples were analysed using commercially available assays, following the manufacturers' instructions. Samples from individual patients were assayed together, to reduce inter-assay variability.
EPO was measured using a quantitative sandwich enzyme-linked immunosorbent assay (R + D Systems Europe Ltd, Abingdon). In brief, serum samples were incubated in microtitre plates precoated with a monoclonal antibody to EPO and bound EPO was detected using an enzyme-linked polyclonal antibody speci®c for EPO. Optical density values obtained at 450 nm were compared to those obtained for a series of standards covering the range 2.5±200 mIU/ml, with the normal range for this assay being 3.5±16.6 mIU/ml. IL-6 was measured by an enzyme ampli®ed sensitivity immunoassay technique, based on an oligoclonal detection system (Medgenix Diagnostics, Brussels, Belgium). Brie¯y, serum samples were incubated in microtitre plates pre-coated with a cocktail of monoclonal antibodies to IL-6 and bound cytokine was detected by the addition of complementary monoclonal antibodies to IL-6, conjugated to horseradish peroxidase. Optical density values obtained at 450 nm were compared to those obtained for a series of standards covering the range 10±2000 pg/ml, the normal range being <10 pg/ml.
A quantitative sandwich enzyme immunoassay was used to measure serum ferritin (Cambridge Life Sciences, UK). Brie¯y, serum samples were incubated with monoclonal antibody-coated micropins speci®c for human liver ferritin. Bound ferritin was detected by incubation with complementary anti-ferritin antibodies conjugated to horseradish peroxidase. Optical density values obtained at 490 nm were compared to those for standards covering the range of 15±500 ng/ ml, the normal range for females being 6±120 ng/ml and that for males 10±400 ng/ml.
Haemoglobin concentrations were measured using a Coulter counter (Coulter, USA) according to the manufacturer's recommended procedure. The normal range of Hb for females was 12±16 g/dl and that for males 13.5±17.5 g/dl.
Analysis of results
In order to exclude iron de®ciency as a confounding factor, we identi®ed patients who had co-existing iron de®ciency and ACD by using baseline serum ferritin levels as an indirect measure of iron stores. As ferritin is an acute-phase protein, higher levels are compatible with iron de®ciency in rheumatoid patients than in patients without in¯ammatory disease. In RA patients, a serum ferritin level of <60 ng/ml has been shown to be a reliable indicator of iron de®ciency with a high degree of sensitivity [38, 39] . Patients with pre-infusion ferritin levels of <60 ng/ml were therefore excluded from analysis.
The placebo, and 1 and 10 mg/kg cA2 groups were compared using the Mann±Whitney U-test. Spearman's ranked coecient of correlation was used to assess the relationship between dierent parameters. In view of the inclusion of both males and females in this study and the dierence in normal Hb values according to sex, analysis was performed on the change from baseline.
RESULTS
Baseline (pre-infusion) demographic and laboratory data for the three treatment groups are shown in Table I . Sixteen of the 64 patients studied had a baseline ferritin of <60 ng/ml, indicating iron de®ciency [38] , and were excluded from further analysis. Of the 48 remaining patients, 33 had Hb concentrations below the normal range for their sex and were classi®ed as having ACD. Median circulating EPO levels were within the normal range for all three groups at baseline, although 13 of the 48 individual values were elevated. Median circulating IL-6 values were high in all groups at baseline, with all but three patients showing values above the normal range (Table I and data not shown). There were no signi®c-ant dierences between the three treatment groups for any laboratory measurement at baseline.
Changes in Hb, EPO and IL-6 over the course of the study are summarized by treatment group in Table II . Patients treated with high-dose cA2 showed a small but signi®cant improvement in Hb in the 4 weeks following infusion, most marked at week 2, while the placebo group showed a larger reduction (Fig. 1 ). Patients treated with low-dose cA2 showed maintenance of baseline Hb. The signi®cance of the changes in median Hb is underlined by an analysis of the proportion of patients who had ACD before and after treatment: 87% of patients treated with highdose cA2 had ACD at the start of the study, compared with 73% 4 weeks after infusion. In contrast, the percentage of ACD patients in the placebo group rose from 64 to 86% over the same time period.
EPO levels rose in the placebo group at 2 and 4 weeks post-infusion, but fell in the 10 mg/kg cA2-treatment group at 2 weeks, reaching statistical signi®cance compared to the placebo-treated patients (P < 0.05) (Fig. 2) . IL-6 levels also fell signi®cantly in both cA2-treated groups compared to placebo (P < 0.001 at 2 weeks; Fig. 3 ), as previously fully reported [40] . After pooling the results for all three treatment groups, there was a signi®cant inverse relationship between Hb and EPO levels at baseline (r = À0.575, P < 0.001; Fig. 4 ) and between the change from baseline in Hb and EPO at 2 weeks (r = À0.549, P < 0.001; Fig. 5 ). There was a weaker but still signi®cant correlation at 4 weeks post-infusion (r = À0.369, P < 0.05). Change in IL-6 also showed a signi®cant negative correlation with change in Hb at 2 weeks (r = À0.402, P < 0.01) and at 4 weeks post-infusion (r = À0.449, P < 0.001). Hb, haemoglobin; EPO, erythropoietin; IL-6, interleukin-6. Normal ranges: Hb 12±16 g/dl (females), 13.5±17.5 g/dl (males); EPO 3.3±16.6 mIU/l; IL-6 < 10 pg/ml. *Excluding patients with baseline ferritin <60 ng/ml. 6Median (interquartile range).
FIG. 1.ÐChange in haemoglobin (Hb) at 2 and 4 weeks post-infusion compared to baseline levels in the three dierent treatment groups. **P < 0.01; ***P < 0.001; Mann±Whitney U-test.
FIG. 2.Ð Change in erythropoietin (EPO) at 2 and 4 weeks post-
infusion compared to baseline levels in the three dierent groups. *P < 0.05; Mann±Whitney U-test.
DISCUSSION
The results of this study are consistent with earlier reports [1] in demonstrating a high incidence of anaemia in RA. Approximately 60% of our study group were anaemic at baseline and ACD was found to account for 67% of these, emphasizing the relative importance of this condition in RA.
Our data show that cA2 therapy not only improves parameters of disease activity such as joint scores, pain and CRP [36] , but also helps to correct ACD. Although the improvement in median Hb following cA2 administration was small in absolute terms, it took place over a short time period (4 weeks), occurred despite a signi®cant venesection (H500 ml) and contrasted with a larger fall in median Hb in patients treated with placebo. The dierence between the treatment groups was highly statistically signi®c-ant.
Although the improvement in Hb seen in cA2-treated patients may re¯ect the reduction in their disease activity, an alternative explanation is that cA2 inhibits a direct eect of TNF-a on erythropoiesis. By measuring circulating cytokines in these patients, we were able to test the hypothesis that TNF-a contributes to ACD in RA by inhibiting EPO production. This notion would predict a rise in circulating EPO following cA2 administration in vivo, with no change or even reciprocal changes in placebo patients. In the event, however, we saw the opposite, with a fall in EPO in cA2-treated patients and a rise in those receiving placebo.
These ®ndings suggest that the major eect of TNF-a in ACD is not through inhibition of EPO production and that, instead, TNF-a may act directly to inhibit red cell formation in the bone marrow. Anaemia is known to be a major stimulus of EPO production, and is thought to regulate its levels via a feedback control system [41] . Such a regulatory mechanism could explain our ®ndings that improve- FIG. 4 .Ð Correlation between baseline haemoglobin (Hb) and erythropoietin (EPO) levels using data from all three treatment groups. Each point represents an individual patient. *P < 0.001; Spearman's ranked correlation coecient. Hb, haemoglobin; EPO, erythropoietin; IL-6, interleukin-6. Normal ranges: Hb 12±16 g/dl (females), 13.5±17.5 g/dl (males); EPO 3.3±16.6 mIU/l; IL-6 < 10 pg/ml. *P < 0.05; **P < 0.01; ***P < 0.001 (Mann±Whitney U-test). 6Median change FIG. 3 .Ð Change in interleukin-6 (IL-6) at 2 and 4 weeks post-infusion compared to baseline levels in the three dierent groups. *P < 0.05; ***P < 0.001; Mann±Whitney U-test. ment in Hb following cA2 therapy was accompanied by a reduction in EPO levels and vice versa in the placebo group. Although this study cannot address the question of how TNF-a acts in the marrow, it is likely that it causes a reduction in the sensitivity of erythroblasts to EPO. The ®nding that administration of rhEPO can successfully treat ACD in a variety of clinical situations indicates that this relative insensitivity to EPO can be overcome, provided adequate EPO concentrations are maintained. The rate of response to rhEPO appears to be determined by the degree of RA disease activity and in¯ammation [15] , which in turn may re¯ect TNF-a production. Alternatively, cA2 may prevent the inhibitory eects of TNF-a on erythroid progenitor cell cycling [23] .
cA2 therapy may also improve ACD indirectly by reducing levels of other cytokines thought to play a suppressive role in erythropoiesis, such as IL-6. In support of this, we saw a strong inverse relationship between changes in IL-6 and Hb following cA2.
The site of production of TNF-a relevant to ACD remains to be established, but evidence suggests that the principal source is not the bone marrow macrophages [35] . Raised levels of TNF-a, its receptors and TNF-a mRNA have all been detected within the RA synovial joint [42±44], where there is strong evidence that TNF-a contributes to the development of arthritis [45, 46] . The synovial joint would therefore appear to be the most likely source of TNF-a, circulating levels producing a systemic eect on the bone marrow in ACD.
Improvement in ACD following high-dose oral corticosteroid treatment in RA has been reported recently [47] . Interestingly, Hb showed signi®cant improvement as early as 4 days after prednisolone therapy was instituted and was accompanied by a fall in EPO levels, indicating a mechanism other than increased EPO production. Corticosteroids have been shown to downregulate the production of various inammatory cytokines, such as TNF-a [48] and IL-1 [49] , raising the possibility that the pro-erythrogenic actions of these drugs may also depend on in¯am-matory cytokine inhibition. Improvement of anaemia in RA patients may be of direct bene®t, e.g. by reducing fatigue [15] , and so increasing the ability to cope with everyday activities. Anaemia also contributes to more serious conditions such as cardiac failure, of particular relevance in view of the greater risk of cardiovascular disease in RA patients [50] . Other bene®ts may accrue from interference by cA2 in disordered erythropoiesis in RA: a greater ability to mobilize and incorporate iron from storage sites and macrophages into red cells may reduce iron-assocated free radical formation [51] and thereby indirectly reduce articular disease.
